BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 29, 2020
View Archived Issues
AHR inhibition suppresses Zika infection
Read More
[124/131I]-MSK-PSMA1, a new radioiodinated theranostic agent for PSMA-positive prostate cancer
Read More
[89Zr]DFO-elotuzumab as novel imaging agent in patients with MM
Read More
EBV drives gastric cancer by rewiring host epigenomes
Read More
Suzhou Zelgen Biosciences identifies new MAP3K5 inhibitors
Read More
Dihydroorotate dehydrogenase inhibitors discovered at Janssen
Read More
Cascade (Shanghai) Pharmaceutical Technology patents AMPK activators
Read More
New PDE9 inhibitors synthesized at Nanjing TransThera Biosciences
Read More
Gruenenthal presents glucocorticoid receptor modulators
Read More
Series A financing to support ExeVir's development of VHH-72-Fc for COVID-19
Read More
Enrollment starts in phase IIa study of tegavivint in desmoid tumors
Read More
PIK3C2B blockade protects against ischemic stroke and preserves vascular integrity
Read More
FDA clears first IND application for RLS-0071
Read More
Reata announces investigator-sponsored trial of bardoxolone in patients with COVID-19
Read More
First patient dosed in investigator-initiated study of infigratinib in recurrent glioblastoma
Read More
European Commission grants approval for Xenleta as treatment of CAP
Read More
COVACTA trial of Actemra in severe COVID-19-associated pneumonia misses endpoints
Read More
Phase III REFALS trial of oral levosimendan in ALS does not meet endpoints
Read More
Mucolipin-1 is a therapeutic target in Alzheimer's disease
Read More
Krystal begins phase III study of beremagene geperpavec for dystrophic epidermolysis bullosa
Read More